Ossiam Acquires 435 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Ossiam increased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.7% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 64,833 shares of the pharmaceutical company’s stock after acquiring an additional 435 shares during the period. Ossiam’s holdings in Vertex Pharmaceuticals were worth $26,108,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Advisory Resource Group grew its holdings in shares of Vertex Pharmaceuticals by 3.2% in the third quarter. Advisory Resource Group now owns 1,970 shares of the pharmaceutical company’s stock worth $916,000 after purchasing an additional 61 shares during the last quarter. Anchor Investment Management LLC grew its stake in Vertex Pharmaceuticals by 1,352.3% in the 3rd quarter. Anchor Investment Management LLC now owns 1,583 shares of the pharmaceutical company’s stock worth $736,000 after acquiring an additional 1,474 shares in the last quarter. World Investment Advisors LLC bought a new position in Vertex Pharmaceuticals in the 3rd quarter worth about $24,280,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $2,187,000. Finally, Destination Wealth Management boosted its holdings in shares of Vertex Pharmaceuticals by 4.5% in the third quarter. Destination Wealth Management now owns 3,361 shares of the pharmaceutical company’s stock valued at $1,563,000 after purchasing an additional 144 shares during the period. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

VRTX opened at $489.10 on Friday. The firm’s 50-day moving average price is $486.76 and its 200-day moving average price is $465.20. The company has a market cap of $125.60 billion, a P/E ratio of -222.32, a price-to-earnings-growth ratio of 2.11 and a beta of 0.50. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. As a group, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Ourania Tatsis sold 244 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total value of $111,034.64. Following the transaction, the executive vice president now directly owns 67,695 shares of the company’s stock, valued at approximately $30,805,286.70. This represents a 0.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP David Altshuler sold 3,231 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $500.00, for a total value of $1,615,500.00. Following the sale, the executive vice president now directly owns 26,512 shares of the company’s stock, valued at $13,256,000. This trade represents a 10.86 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 4,315 shares of company stock worth $2,121,012 in the last 90 days. Insiders own 0.20% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on VRTX. Morgan Stanley raised their price objective on Vertex Pharmaceuticals from $450.00 to $459.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 11th. StockNews.com upgraded Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, March 11th. HC Wainwright reiterated a “buy” rating and set a $550.00 target price on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Barclays raised their target price on shares of Vertex Pharmaceuticals from $435.00 to $467.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 11th. Finally, Royal Bank of Canada upped their price target on shares of Vertex Pharmaceuticals from $408.00 to $420.00 and gave the stock a “sector perform” rating in a research report on Tuesday, April 1st. Ten research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $512.41.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.